Haematologists will need to make hard calls about delaying some cancer therapies, moving to shorter treatment regimens and prioritising treatment to only those most at risk if community acquired COVID-19 transmission rates start to climb, according to new clinical guidance. During a SARS-COV-2 (COVID-19) webinar sponsored by Janssen-Cilag to discuss the management of cancer patients ...
Cancer units should prepare for the next transmission phase: experts
26 Apr 2020
Sponsored by Janssen-Cilag Pty Ltd